Study Shows Positive Results For RXi's Anti-Scarring Therapy
Westborough-based RXi Pharmaceuticals said the first double-blind study of its anti-scarring treatment using healthy volunteers had positive results.
The biotechnology company, which focuses on discovering, developing and commercializing medical therapies using RNA-targeted technologies, said its RXI-109 treatment was well tolerated and produced a statistically significant and reduction of connective tissue growth factor (CTGF), a protein that causes abnormal scarring in wounds, depending on dosage
"Based on the animal data, we were confident that RXI-109 would not cause significant side effects or toxicities in this first study, and we are pleased to announce that confirmation today," said RXi President and CEO Dr. Geert Cauwenbergh.
He said significant reductions of CTGF were seen three months after a single dose of RXI-109, suggesting a strong and long-lasting effect on the protein.
Results of RXi's second Phase 1 trial, using multiple doses of RXI-109 are expected to be available next month.
Read more
Westborough’s RXi Buys Firm’s RNAi Assets
WBJ Web Partners
Most Recent
Most Recent
0 Comments